Post-exercise Insulin Reductions in Type 1 Diabetes

This study has been completed.
Diabetes UK
Information provided by (Responsible Party):
Northumbria University Identifier:
First received: February 7, 2012
Last updated: August 17, 2012
Last verified: August 2012

The investigators hypothesise that reducing rapid-acting insulin dose after exercise will help prevent Type 1 diabetes individuals experiencing hypoglycaemia.

Condition Intervention
Type 1 Diabetes
Other: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: The Metabolic and Glycaemic Responses to Reductions in Rapid-acting Insulin Dose After Running Exercise in People With Type 1 Diabetes Mellitus.

Resource links provided by NLM:

Further study details as provided by Northumbria University:

Primary Outcome Measures:
  • 24 hour blood glucose area under the curve [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    24 hour, post-exercise, glucose area under the curve.

Secondary Outcome Measures:
  • Ketogenesis [ Time Frame: 60 minutes before and 24 hours post-exercise ] [ Designated as safety issue: No ]
    Blood beta-hydroxybutyrate concentrations

Estimated Enrollment: 16
Study Start Date: February 2012
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Insulin dose
Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.
Other: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose
Dosage after exercise


Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • T1DM,
  • Male,
  • basal-bolus regimen (insulin glargine / detemir with insulin lispro / aspart),
  • HbA1c < 9.9%,
  • aged 18-50.

Exclusion Criteria:

  • HbA1c > 10%,
  • not treated with basal-bolus (insulin glargine / detemir with insulin lispro / aspart),
  • aged <18 > 50.
  Contacts and Locations
Please refer to this study by its identifier: NCT01531855

United Kingdom
Clinical Research Facility
Newcaslte upon Tyne, Tyne and Wear, United Kingdom, NE1 4LP
Sponsors and Collaborators
Northumbria University
Diabetes UK
Principal Investigator: Daniel J West Northumbria University
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Northumbria University Identifier: NCT01531855     History of Changes
Other Study ID Numbers: west-walker1
Study First Received: February 7, 2012
Last Updated: August 17, 2012
Health Authority: United Kingdom: National Health Service

Keywords provided by Northumbria University:
T1DM, Exercise

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin LISPRO
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions processed this record on April 21, 2014